Policy & Compliance

  • April 20, 2026

    ImmunityBio Stock Fell After FDA Letter, Derivative Suit Says

    Biotechnology company ImmunityBio Inc.'s stock slipped by 21% after misleading statements on a podcast by the company's founder about its lead cancer drug prompted the issuance of a warning letter from the U.S. Food and Drug Administration, according to a shareholder derivative suit in California federal court.

  • April 20, 2026

    PBMs Fail To Freeze Discovery In Mich.'s Drug-Pricing Case

    A pending motion to dismiss the Michigan attorney general's drug-pricing case against multiple pharmacy benefit managers does not preclude the PBMs from handing over agreements between PBMs and pharmacies to the state, a federal judge said in a motion hearing Monday.

  • April 20, 2026

    Doctors Fueled Man's Fatal Opioid Addiction, Philly Jury Told

    Counsel for the family of a man who died of an opioid overdose at age 26 told a Philadelphia jury that his doctors were responsible for pushing treatment plans that allowed him to develop an opioid addiction, leading to his untimely death, pointing to both physicians being paid speakers for the pharmaceutical companies whose medications they prescribed.

  • April 20, 2026

    Justices Mull Limits On Federal Review Of State Cases

    The U.S. Supreme Court on Monday wrestled with the potential impact of reining in — or even scrapping altogether — a 100-year-old doctrine that curbs litigants' ability to go to federal court to try to overturn a state court loss.

  • April 20, 2026

    'Unserious Leaders Are Unsafe': RFK Jr.'s Trans Edict Voided

    An Oregon federal judge struck down Health and Human Services Secretary Robert F. Kennedy Jr.'s efforts to enforce the agency's restrictions on gender-affirming care for minors, finding the restrictions unlawful and criticizing Kennedy's leadership and the policy declaration that introduced the changes. 

  • April 20, 2026

    Justices Won't Block Multimillion-Dollar Health Fraud Retrial

    A man accused of pocketing $12 million as a part of a larger $140 million scheme to defraud public and private healthcare programs can't get out of a second trial, as the U.S. Supreme Court declined to review his case on Monday.

  • April 17, 2026

    9th Circ. Revives Doctor's PeaceHealth Whistleblower Suit

    A Ninth Circuit panel has reinstated a psychiatrist's claims that PeaceHealth Inc. retaliated against him for expressing concerns about potential Medicaid fraud at a Washington hospital, concluding on Friday that the district court overlooked evidence that the employer punished him by not renewing his employment contract.

  • April 17, 2026

    Up Next At High Court: SEC And FCC Enforcement Authority

    The U.S. Supreme Court's final argument session of this term kicks off Monday, when the justices will consider the U.S. Securities and Exchange Commission's authority to seek disgorgement orders against alleged wrongdoers without proving investors were harmed. Here, Law360 breaks down the week's oral arguments.

  • April 17, 2026

    Allstate Says Fla. Surgery Centers Padded Bills For Care

    Seven ambulatory surgery centers, a pain clinic and an anesthesia practice that are all run by Surgery Partners conducted "extraordinarily aggressive treatment" on patients involved in minor car crashes to inflate the bills submitted to Allstate, the insurer told a Florida federal court Friday, alleging it paid millions for unnecessary treatment.

  • April 17, 2026

    Bill Floated To Nix Medical Residency Antitrust Exemption

    U.S. Sen. Mike Lee, R-Utah, has introduced legislation to repeal an antitrust exemption given to the medical residency matching program by Congress two decades ago, over concerns about wages and a bottleneck of medical school graduates.

  • April 17, 2026

    Aramark Joins NJ Insulin Pricing Suits Against PBMs

    Aramark Services Inc. joined multidistrict litigation accusing CVS and pharmacy benefit managers of colluding to inflate the price of insulin.

  • April 17, 2026

    Doc Says Texas Man Can't Sue Over Mailed Abortion Pills

    A Texas man suing his ex-girlfriend's out-of-state doctor for prescribing mail-order abortion pills can't prove that the doctor caused the wrongful death of their unborn child, the doctor told a federal court, saying the case should be dismissed because he's not responsible for the woman's actions. 

  • April 16, 2026

    Trump Taps Ret. Rear Admiral Schwartz As New CDC Chief

    President Donald Trump on Thursday nominated Dr. Erica Schwartz, a retired rear admiral who served in the U.S. Coast Guard and as deputy surgeon general in the first Trump administration, to be the Centers for Disease Control and Prevention's next director.

  • April 16, 2026

    Feds Can't Stay Trans Healthcare Orders During Appeal

    The Trump administration won't be able to enforce two executive orders that ban federal funding for gender-affirming care for patients under the age of 19 while the federal government appeals a nationwide injunction blocking the orders, the Fourth Circuit ruled Thursday. 

  • April 16, 2026

    DOL Benefits Chief Pressed On Labor Secretary's Conduct

    The head of the U.S. Department of Labor's employee benefits arm faced tough questions from House Democrats at an oversight hearing Thursday, fielding questions about the labor secretary's on-the-job conduct as well as the DOL's take on mental health parity enforcement. 

  • April 15, 2026

    Aluminum Co. Settles Trans Worker's Suit Over Health Plan

    A subsidiary of Kaiser Aluminum has agreed to resolve a lawsuit claiming it discriminated against transgender employees by excluding coverage for medical treatments related to gender-affirming care from its health plan, according to a filing in Washington federal court.

  • April 15, 2026

    NC Judge Won't Undo $4M Philips Copyright Verdict

    A North Carolina federal judge has refused to erase a $4 million jury verdict against independent service organization Transtate Equipment Co. for violations of the Digital Millennium Copyright Act, saying trial evidence provided a "firm basis" to support the jury's statutory damages award.

  • April 14, 2026

    4th Circ. Revives Pharma Bid To Block Maryland's 340B Law

    A split Fourth Circuit panel on Tuesday tossed a Maryland district court's order denying a preliminary injunction to pharmaceutical manufacturers that have challenged a state law addressing drug delivery in the federal 340B discount program, pointing to its recent ruling that West Virginia's similar statute is likely preempted.

  • April 14, 2026

    Justices Told That Eli Lilly's FCA Qui Tam Challenge Too Late

    A whistleblower who secured a $183 million trial win against Eli Lilly urged the U.S. Supreme Court on Tuesday to reject its constitutional challenge over his ability to sue for the federal government, arguing the drugmaker's arguments came too late.

  • April 14, 2026

    Colo. Justices Weigh Bid To Restore Trans Youth Care

    Colorado's justices pushed Children's Hospital Colorado on Tuesday to explain how its decision to halt gender-affirming care for transgender youth patients is not discriminatory, even amid the federal government's threats to cut funding for providers that offer the care to children and adolescents.

  • April 14, 2026

    Trade Group Latest To Sue Wash. Over 340B Drug Pricing Law

    Pharmaceutical Research and Manufacturers of America claims a new Washington state law attempts to illegally reshape the federal 340B Drug Pricing Program and singles out participating drugmakers with burdensome regulations, according to a fresh federal lawsuit that follows similar constitutional challenges mounted by Novartis and AbbVie.

  • April 14, 2026

    Ga. Providers Say Rutledge Bars United's Preemption Win

    Medical providers are urging a Georgia federal court to deny United's bid for an early win in its case seeking a declaration that the providers' purported attempt to claw back reimbursements for out-of-network services are preempted, arguing that state-law claims involving employee benefits aren't preempted by federal benefits law.

  • April 14, 2026

    FDA Offers Guidance On Safety Testing For Gene-Editing Tech

    The U.S. Food and Drug Administration on Tuesday issued draft guidance recommending steps drug companies should take to evaluate the safety of gene-editing technology as they seek federal approval for cutting-edge treatments aimed at genetic diseases.

  • April 14, 2026

    Doctors Hope Justices Maintain Shield Against Med Mal Suits

    A case headed to the U.S. Supreme Court next week could roll back a legal doctrine that physicians say is key to protecting them from frivolous medical malpractice suits filed by patients who've already lost in state court.

  • April 14, 2026

    7th Circ. Suggests High Court Ruling Supports Ark. PBM Rule

    The Seventh Circuit appeared reluctant Tuesday to revive a union fund's challenge to an Arkansas rule making health plans disclose pharmacy compensation and pay fees, with judges pointing to a 2020 U.S. Supreme Court ruling that permitted state cost regulations on pharmacy benefit managers.

Expert Analysis

  • Criminal Healthcare Fraud Takeaways From 4th Circ. Reversal

    Author Photo

    After the Fourth Circuit reversed a doctor’s postconviction acquittal in U.S. v. Elfenbein last month, defense attorneys should consider three strategies when handling complex criminal healthcare matters, says Jonathan Porter at Husch Blackwell.

  • AG Watch: Texas Embraces The MAHA Movement

    Author Photo

    Attorneys at Kelley Drye examine Texas Attorney General Ken Paxton's actions related to the federal Make America Healthy Again movement, and how these actions hinge on representations or omissions by the target companies as opposed to specific analyses of the potential health risks.

  • How States Are Regulating Health Insurers' AI Usage

    Author Photo

    The absence of a federal artificial intelligence framework positions states as key regulators of health insurers’ AI use, making it important for payors and service providers to understand the range of state AI legislation being passed in California and elsewhere, and consider implementing an AI-focused compliance infrastructure, say attorneys at Ropes & Gray.

  • HHS Plan To Cut Immigrant Benefits Spurs Provider Questions

    Author Photo

    A recent notice from the U.S. Department of Health and Human Services identifying new federal public benefit programs for which nonqualified aliens are not eligible may have a major impact on entities that participate in these programs — but many questions remain unanswered, say attorneys at Foley.

  • Noncompete Forecast Shows Tough Weather For Employers

    Author Photo

    Several new state noncompete laws signal rough conditions for employers, particularly in the healthcare sector, so employers must account for employees' geographic circumstances as they cannot rely solely on choice-of-law clauses, say lawyers at McDermott.

  • Previewing State Efforts To Regulate Mental Health Chatbots

    Author Photo

    New York, Nevada and Utah have all recently enacted laws regulating the use of artificial intelligence to deliver mental health services, offering early insights into how other states may regulate this area, say attorneys at Goodwin.

  • How DOJ's New Data Security Rules Leave HIPAA In The Dust

    Author Photo

    The U.S. Department of Justice's recently effective data security requirements carry profound implications for how healthcare providers collect, store, share and use data — and approach vendor oversight — that go far beyond the Health Insurance Portability and Accountability Act, say attorneys at Nelson Mullins.

  • Texas Med Spas Must Prepare For 2 New State Laws

    Author Photo

    Two new laws in Texas — regulating elective intravenous therapy and reforming healthcare noncompetes — mark a pivotal shift in the regulatory framework for medical spas in the state, which must proactively adapt their operations and contractual practices, says Brad Cook at Munsch Hardt.

  • DOJ-HHS Collab Crystallizes Focus On Health Enforcement

    Author Photo

    The recently announced partnership between the U.S. Department of Justice and U.S. Department of Health and Human Services to combat False Claims Act violations, following a multiyear trend of high-dollar DOJ recoveries, signals a long-term enforcement horizon with major implications for healthcare entities and whistleblowers, say attorneys at RJO.

  • How The Healthline Privacy Settlement Redefines Ad Tech Use

    Author Photo

    The Healthline settlement is the first time California has drawn a clear line in the sand around how website tracking must function in practice, so if your site uses tracking technologies, especially around sensitive content like health or finance, regulators are inspecting your website's back end, not just its banner, say attorneys at Baker Donelson.

  • How Sweeping Budget Bill Shakes Up Health Industry

    Author Photo

    With the recently passed One Big Beautiful Bill Act marking one of the most significant overhauls of federal health policy since the passage of the Affordable Care Act, providers, managed care organizations and life sciences companies must now shift focus from policy review to implementation planning, say advisers at Holland & Knight.

  • New DOJ Penalty Policy Could Spell Trouble For Cos.

    Author Photo

    In light of the U.S. Department of Justice’s recently published guidance making victim relief a core condition of coordinated resolution crediting, companies facing parallel investigations must carefully calibrate their negotiation strategies to minimize the risk of duplicative penalties, say attorneys at Debevoise.

  • A Look At Key 5th Circ. White Collar Rulings So Far This Year

    Author Photo

    In the first half of 2025, the Fifth Circuit has decided numerous cases of particular import to white collar practitioners, which collectively underscore the critical importance of meticulous recordbuilding, procedural compliance and strategic litigation choices at every stage of a case, says Joe Magliolo at Jackson Walker.